Prognostic markers of disease activity in Hodgkin's disease

Leukemia and Lymphoma

Volumn 29, Issue 3-4, 1998, Pages 383-389

  Martinow, Allan J ^a   Yuen, Kally ^a   Cooper, Ian A ^a   Matthews, Jane P ^a   Juneja, Surenda ^a   Wolf, Max ^a   Januszewicz, Henry ^a   Prince, H Miles ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Alkaline phosphatase; Copper; ESR; Hodgkin's disease; Nucleosides

Indexed keywords

ALKALINE PHOSPHATASE; COPPER; LIVER ENZYME; NUCLEOSIDE;

ADULT; ARTICLE; COPPER BLOOD LEVEL; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LIVER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; URINARY EXCRETION;

EID: 0031815454     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809068574     Document Type: Article

References (23)

1. Specht, L. (1991). Prognostic factors in Hodgkin's disease. Cancer Treatment Reviews, 18, 21-53.
2. Proctor, S. J., Taylor, P., Mackie, M. J., Donnan, P., Boys, R., Lennard, A. and Prescott, R. J. (1992). A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Leukemia and Lymphoma, 7(suppl 1), 17-20.
3. Proctor, S. J., Taylor, P., Donnan, P., Boys, R., Lennard, A. and Prescott, R. J. (1991). A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer, 27, 624-9.
4. Thorling, E. B. and Thorling, K. (1976). The clinical usefulness of serum copper determination in Hodgkins disease. A retrospective study of 241 patients. Cancer, 38, 225-31.
5. Thyss, A., Schneider, M., Caldani, C., Viot, M. and Bourry, J. (1985). Reevaluation of alkaline phosphatase measurement during Hodgkins disease by electrophoretic separation. British Journal of Cancer, 52, 183-7.
6. Simmons, A. V., Spiers, A. S. and Fayers, P. M. (1973). Haematological and clinical parameters in assessing activity in Hodgkins disease and other malignant lymphomas. Quarterly Journal of Medicine, 165, 111-24.
7. Aisenberg, A. C., Kaplan, M. M., Rieder, S. V. and Goldman, J. M. (1970). Serum alkaline phosphatase at the onset of Hodgkins disease. Cancer, 26, 318-26.
8. Margerison, A. C. and Mann, J. R. (1985). Serum copper, serum ceruloplasmin, and erythrocyte sedimentation rate measurements in children with Hodgkins disease, non-Hodgkins lymphoma and nonmalignant lymphadenopathy. Cancer, 55, 1501-6.
9. Gupta, S. K., Shukla, V. K., Gupta, V. and Gupta, S. (1994). Serum trace elements and Cu/Zn in malignant lymphomas in children. Journal of Tropical Paediatrics, 40, 185-7.
10. Straus, D. J., Gaynor, J. J., Myers, J., Merke, D. P., Caravelli, J., Chapman, D., Yahalom, J. and Clarkson, B. D. (1990). Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol, 8, 1173-86.
11. Killman, N. M. (1993). Hodgkin's disease: a challenge to the classical staging system. Leukemia, 7, 1910.
12. Proctor, S. J. and Taylor, P. R. A. (1993). Classsial staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: the case for the objective use of prognostic factor information in addition to classical staging. Leukemia, 7, 1911-4.
13. Specht, L. (1993). Prognostic factor studies in Hodgkin's disease: problems and pitfalls. Leukemia, 7, 1915-6.
14. Borek, E., Waalkes, T. P. and Gehrke, C. W. (1993). Tumour markers derived from nucleic acid components. Cancer Detection and Prevention, 6, 67-71.
15. Borek, E., Baliga, B. S., Gehrke, C. W., Belman, S., Troll, W. and Waalkes, T. P. (1977). High turnover rate of transfer RNA in tumour tissue. Cancer Research, 37, 3362-6.
16. Rasmuson, T., Bjork, G. R., Damber, L., Holm, S. E., Jacobsson, L., Jeppsson, A., Littbrand, B., Stigbrand, T. and Westman, G. (1983). Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and modified nucleosides as biological markers in malignant lymphomas. Cancer Research, 84, 331-43.
17. Murphy, T. L., Cooper, I. A., Wray, G. R., Ironside, P. N. J. and Mathews, J. (1976). Transfer RNA and transfer RNA methylase activity in spleens of patients with Hodgkins disease and histiocytic lymphoma. J Nat Cancer Inst, 56, 215-9.
18. Murphy, T. L. and Cooper, I. A. (1982). Pattern of isoaccepting transfer RNAs common to 26 patients with Hodgkins Disease. Cancer Research, 42, 3887-91.
19. Pinkard, K. J., Cooper, I. A., Motteram, R. and Turner, C. N. (1972). Purine and Pyrimidine excretion in Hodgkins Disease. J Nat Cancer Inst, 49, 27-38.
20. Cooper, I. A., Wray, G. R. and Murphy, T. L. (1977). Urinary excretory patterns of tRNA degradation products; A marker of Hodgkins cell metabolism? Eur J Cancer, 13, 1309-12.
21. Rasmuson, T. and Bjork, G. R. (1995). Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncologica, 34, 61-7.
22. Davis, G. E., Suits, R. D., Kuo, K. C., Gehrke, C. W., Woalkes, T. P. and Borek, E. (1977). High performance liquid Chromatographic separation and quantitation of nucleosides in urine and some other biological fluids. Clin Chem, 23, 1427-35.
23. Gehrke, C. W., Kuo, K. C, Woalkes, T. P. and Borek, E. (1979). Patterns of urinary excretion of modified nucleosides. Cancer Research, 39, 1150-3.